Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
out at 4.76, missed my 3%, got a little gun shy last time ridding it down to 2.30 . Good luck to ya Tree.
Back in @ 4.67 might just take a 3 - 5 % if I can get it today . Remember market is closed on Monday. GLTA and have a good week end
Emotion got the best of me. ( need to keep that in check ) However, this was a big stake for me. 10k shs ,sold calls on 4k, 50% on 6k
I'm out at 6.00, still have some shares that will be called away at 4.00
Thanks sheep
Per think or swim new feed, resume trading at 5:40 pm et
panel is tuff, and should be,but, sounds like "CHTP" is holding it's own. they are A.B.C. LOL hope they pull it off also, would start my new year out well.
Meeting webcast website at
https://collaboration.fda.gov/crdacjan14
log in as guest, no pass word needed
Aafia Chaudhry will blog the panel live today on " the street"
http://www.thestreet.com/story/12224995/1/chelsea-therapeutics-northera-fda-panel-live-blog.html
I've seen more go down . I'm out for now. no loss . GLTA
Will look to re-enter after it clams down.
option Alert, from think or swim news feed. Feb. $5.00 calls 4,966 contracts trade at ask .65
can't copy and paste.
good luck to us all
FWIW ? I use Fidelity as well, but monitor on think or swim. you got a good price. GLTA
Gap is closed
Saw this over on Sheff's board, jumped in also at .67 ,it still might have to close the gap at .64/.66 hope we both/all do great.
Fox, Good for you. ya made bank, that's what it's all about. I also jumped back in (small) yesterday .0631 holding out for a little more in the .07's
GLTA
IMHO, I think the same guy that writes the headline stories for Nuvilex, may be the same guy the that writes the Forward-looking statements for all companies. LOL
Not bashing , I have flip this one, will still watch for a while.
GLTA
IMO Amarin got greedy, It did not want to sell the speculation ( and risk ) of the NEC,MARINE, ect... They wanted it all.
My shares will more then likely recover over time,will be taking a big hit on my jan. calls Good luck to all.
NuPathe to cut half its jobs to conserve cash
Reuters) - NuPathe Inc said it would cut half of its workforce to reduce costs and focus on the regulatory approval of its experimental migraine patch.
The company said it will reduce expenses related to the marketing of the pain patch and on earlier-stage drug candidates.
NuPathe has 37 employees, according to Thomson Reuters data.
It also plans to delay the application for its experimental treatment for schizophrenia and bipolar disorder until it finds a partner.
NuPathe is trying to raise about $28 million in a proposed financing and expects the cost cut initiatives, along with the proceeds, to be sufficient to fund operations into the fourth quarter of 2013.
The company, which has a market capitalization of about $55 million, had cash and cash equivalents of $7.5 million as of June 30.
In July, the U.S. Food and Drug Administration accepted a resubmission of the company's approval application for the migraine patch, called NP101.
NuPathe shares closed at $3.71 on Monday on the Nasd
Any thoughts on the Confidential Treatment Order ?
HZNP dropping
15:48:21 $15.11 10,700shs ????
High Five to all !
Web site taken down
Amarin post Vascepa web site.http://uat.amarin.strategicedge.com/vascepa/index.html
C'mon be nice
It did open my eyes wide. picked up some aug.15 calls
closing the gap ?
shake shake shake shake this tree
O.K. I'll bite, why would insider selling be good?
Do we say " egg on facebook " ??
Looks like hi vol. down right now
I just love these " exploration " companies down here in texas, they just seem to go on, and on, and on..........
kind of like a city council , we need a $10,mil. study for this, and a $20,mil. study for that, and $100,mil. to keep up with the on going studies...... they just go down the trail that gos on and on and on...........
GLTA
Just saying...... Caprock Risk Management, LLC, has a 12-month contract with Pegasi Energy Resources Corporation for $4,000 a month starting March 15, 2012 to launch and maintain independent fee-based research on the Company
GSK after Human Genome again.
By Ben Hirschler
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
The decision to go hostile with the $13 a share cash tender offer sets GSK up for a battle with those Human Genome investors who believe it is not offering enough.
"They will do fantastically well out of this - at $13 it is a steal," said Mark Evans, a fund manager at Taube Hodson Stonex, the sixth largest investor in Human Genome with a 5.6 percent stake.
"I still think it is very likely that they will have to pay more."
Human Genome's board spurned the approach from Britain's biggest drugmaker last month, saying it did not reflect the company's inherent value. GSK insists its bid, representing an 81 percent premium, is full and fair.
Human Genome shares closed at $14.62 on Tuesday - above GSK's offer price but still only half the peak touched in April last year, when investors' hopes were higher for its new drug for the autoimmune condition lupus, Benlysta.
GSK and the U.S. pioneer of gene-based drug discovery sell Benlysta together and the companies are collaborating on two other experimental drugs for diabetes and heart disease that could become significant sellers.
Buying Human Genome would give GSK full rights to these partnered drugs.
A spokeswoman for GSK declined to say exactly when this week the tender would be launched. It will remain open for 20 business days. The standard practice is for tender offers to proceed only if the buyer gets a majority of the shares, but there is scope to extend or amend the offer.
NO NEED TO JOIN REVIEW PROCESS
Human Genome has hired Goldman Sachs and Credit Suisse to explore strategic alternatives, including a possible sale of the company, and has invited GSK to join the process.
But GSK, which is being advised by Lazard and Morgan Stanley, said on Wednesday it would not participate in that strategic review.
"GSK's participation in the process is unnecessary as its offer is not conditioned on due diligence or financing and can be completed expeditiously," it said in a statement.
"It is important for HGS shareholders to understand that GSK is committed to proceeding with its offer."
GSK's partnership with the Rockville, Maryland-based company goes back two decades, and even though the deals between the two companies have no tricky change-of-control clauses, analysts doubt another company will emerge as a "white knight" bidder.
Any non-GSK acquirer would only get partial control of the key drugs, which could make it an unappetizing target.
GSK and Human Genome share rights to Benlysta, but GSK is in charge of developing both the new heart drug darapladib and albiglutide for diabetes. As a result, the British-based company already owns most of the commercial upside to these products.
HOLDING THE CARDS
"Glaxo holds a lot of the cards in this story," said Navid Malik, an analyst at Cenkos Securities.
"I think Glaxo will have to raise its offer but probably not significantly ... the right price for shareholders in Human Genome would be in the mid to high-teens (dollars per share)."
Many shareholders bought into Human Genome when the shares surged from some $3 in July 2009 after impressive clinical trials results with Benlysta, when they may have paid around $15-18 a share.
Drugmakers around the world are seeking deals to get new drugs into the pipeline as older products lose patent protection, and GSK's bid for Human Genome is the latest in a recent wave of takeover activity in the sector.
AstraZeneca last month agreed to buy Ardea Biosciences for $1.26 billion to access a promising gout drug, while Roche made an ultimately unsuccessful bid for gene sequencing firm Illumina in January.
GSK said its preference was to complete the deal on "a friendly basis in a timely fashion" and it remained willing to discuss its offer with Human Genome at any time.
(Reporting by Ben Hirschler; Editing by Will Waterman and Philippa Fletcher)
why would this drop on the release of earnings on the 7th in market hrs instead of the 9th after hrs.? the 9th is what TOS chart shows.
Benzinga still pumping rumors. said stock could be 30 - 40 over next 2 yrs.
I don't have the link, I don't get there news letter. saw it on think or swim's live news
Go for it
Ref:"The best thing that can happened for flippers...rev split buys within the 20 days"
I really don't understand this trade
Then Babkie can give you 1 sh. of a spinoff co. for 500 shs. of Zevotek. Do you remember 'Diet Coffee'
IMHO Also I have 11 shares now GLTA
Looks like they might be going for AH
Can't say I really like that.
kookie I like that link. thanks
think or swimm news feed, ck out your real time.